Please enable JavaScript to continue using this application.

Compare $DTIL vs $LYEL | Chartloom

Compare

$DTIL vs $LYEL

Precision BioSciences Inc · Lyell Immunopharma Inc

DTIL

Precision BioSciences Inc

LYEL

Lyell Immunopharma Inc

Compare $DTIL vs $LYEL

Comparing Precision BioSciences Inc and Lyell Immunopharma Inc

DTILPrecision BioSciences Inc

LYELLyell Immunopharma Inc

DTILPrecision BioSciences Inc

Market cap

$173M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

80.94x

Rev growth (TTM)

3473.0%

YTD performance

63.9%

52W performance

17.9%

FCF yield

-30.2%

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DTIL

LYEL

Detailed metrics comparison

DTIL

Precision BioSciences Inc

LYEL

Lyell Immunopharma Inc

Market Cap

DTIL$173M

LYEL$203M

Enterprise Value

DTIL$110M

LYEL$130M

Price

DTIL$6.72

LYEL$8.71

P/E Ratio

DTILN/A

LYELN/A

P/S Ratio

DTIL3.85x

LYEL7,526.09x

EV/Sales

DTIL2.44x

LYEL4,822.94x

EV/EBITDA

DTIL0.00x

LYEL0.00x

P/B Ratio

DTIL3.85x

LYEL0.97x

P/FCF Ratio

DTILN/A

LYELN/A

EV/FCF

DTIL-2.09x

LYEL-0.74x

PEG Ratio

DTILN/A

LYELN/A

Forward P/E (NTM)

DTILN/A

LYELN/A

Forward P/S (NTM)

DTIL80.94x

LYEL16,911.71x

Revenue (TTM)

DTIL$45M

LYEL$27K

Revenue Growth (YoY)

DTIL3473.0%

LYEL-55.0%

Forward Rev Growth

DTIL-28.2%

LYEL7184.7%

Gross Margin (TTM)

DTIL0.0%

LYEL0.0%

Operating Margin (TTM)

DTIL0.0%

LYEL0.0%

EBITDA Margin (TTM)

DTIL-78.0%

LYEL-669059.3%

Net Margin (TTM)

DTIL-117.0%

LYEL-920285.2%

FCF Margin (TTM)

DTIL-116.3%

LYEL-648763.0%

Net Income (TTM)

DTIL$-53M

LYEL$-248M

FCF (TTM)

DTIL$-52M

LYEL$-175M

EPS (TTM)

DTIL-$2.04

LYEL-$10.64

ROE (TTM)

DTIL-9160.0%

LYEL-9162.0%

ROA (TTM)

DTIL-4074.0%

LYEL-7050.0%

ROIC (TTM)

DTIL-6594.0%

LYEL-9162.0%

Cash

DTIL$86M

LYEL$73M

Debt

DTIL$22M

LYEL$0

Net Cash/Debt

DTIL$64M

LYEL$73M

Current Ratio (TTM)

DTIL12.82x

LYEL5.36x

Quick Ratio (TTM)

DTIL12.26x

LYEL5.12x

Debt/Equity (TTM)

DTIL0.50x

LYEL0.00x

Debt/Assets (TTM)

DTIL0.0%

LYEL0.0%

Interest Coverage (TTM)

DTILN/A

LYELN/A

Net Debt/EBITDA (TTM)

DTIL0.00x

LYEL0.00x

Beta

DTIL1.44

LYEL-0.04

52W Performance

DTIL17.9%

LYEL-52.3%

YTD Performance

DTIL63.9%

LYEL-69.9%

% from 52W High

DTIL-30.1%

LYEL-80.6%

% from 52W Low

DTIL90.4%

LYEL6.1%

Asset Turnover (TTM)

DTIL0.36x

LYEL0.00x

FCF Yield (TTM)

DTIL-30.2%

LYEL-86.2%

Earnings Yield (TTM)

DTIL-30.4%

LYEL-122.3%

Dividend Yield (TTM)

DTILN/A

LYELN/A

Rule of 40

DTIL3,356.7

LYEL-648,818.0

EV/GP/RG

DTILN/A

LYELN/A

Ticker research

View DTIL research View LYEL research

Metric	DTIL Precision BioSciences Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$173M	$203M
Enterprise Value	$110M	$130M
Price	$6.72	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	3.85x	7,526.09x
EV/Sales	2.44x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.85x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.09x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	80.94x	16,911.71x
Revenue & Growth
Revenue (TTM)	$45M	$27K
Revenue Growth (YoY)	3473.0%	-55.0%
Forward Rev Growth	-28.2%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-78.0%	-669059.3%
Net Margin (TTM)	-117.0%	-920285.2%
FCF Margin (TTM)	-116.3%	-648763.0%
Net Income (TTM)	$-53M	$-248M
FCF (TTM)	$-52M	$-175M
EPS (TTM)	-$2.04	-$10.64
ROE (TTM)	-9160.0%	-9162.0%
ROA (TTM)	-4074.0%	-7050.0%
ROIC (TTM)	-6594.0%	-9162.0%
Financial Health
Cash	$86M	$73M
Debt	$22M	$0
Net Cash/Debt	$64M	$73M
Current Ratio (TTM)	12.82x	5.36x
Quick Ratio (TTM)	12.26x	5.12x
Debt/Equity (TTM)	0.50x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.44	-0.04
52W Performance	17.9%	-52.3%
YTD Performance	63.9%	-69.9%
% from 52W High	-30.1%	-80.6%
% from 52W Low	90.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.00x
FCF Yield (TTM)	-30.2%	-86.2%
Earnings Yield (TTM)	-30.4%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,356.7	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View DTIL research	View LYEL research

Valuation

P/S Ratio

DTIL

3.85x

LYEL

7,526.09x

EV/FCF

DTIL

-2.09x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

DTIL

3473.0%

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

DTIL

-28.2%

Profitability & performance

Gross Margin

DTIL

0.0%

LYEL

0.0%

ROE

DTIL

-9160.0%

LYEL

-9162.0%

FCF Yield %

DTIL

-30.2%

LYEL

-86.2%

52-Week Performance

DTIL

17.9%

LYEL

-52.3%

Detailed metrics comparison

DTIL

Precision BioSciences Inc

LYEL

Lyell Immunopharma Inc

Market Cap

DTIL$173M

LYEL$203M

Enterprise Value

DTIL$110M

LYEL$130M

Price

DTIL$6.72

LYEL$8.71

P/E Ratio

DTILN/A

LYELN/A

P/S Ratio

DTIL3.85x

LYEL7,526.09x

EV/Sales

DTIL2.44x

LYEL4,822.94x

EV/EBITDA

DTIL0.00x

LYEL0.00x

P/B Ratio

DTIL3.85x

LYEL0.97x

P/FCF Ratio

DTILN/A

LYELN/A

EV/FCF

DTIL-2.09x

LYEL-0.74x

PEG Ratio

DTILN/A

LYELN/A

Forward P/E (NTM)

DTILN/A

LYELN/A

Forward P/S (NTM)

DTIL80.94x

LYEL16,911.71x

Revenue (TTM)

DTIL$45M

LYEL$27K

Revenue Growth (YoY)

DTIL3473.0%

LYEL-55.0%

Forward Rev Growth

DTIL-28.2%

LYEL7184.7%

Gross Margin (TTM)

DTIL0.0%

LYEL0.0%

Operating Margin (TTM)

DTIL0.0%

LYEL0.0%

EBITDA Margin (TTM)

DTIL-78.0%

LYEL-669059.3%

Net Margin (TTM)

DTIL-117.0%

LYEL-920285.2%

FCF Margin (TTM)

DTIL-116.3%

LYEL-648763.0%

Net Income (TTM)

DTIL$-53M

LYEL$-248M

FCF (TTM)

DTIL$-52M

LYEL$-175M

EPS (TTM)

DTIL-$2.04

LYEL-$10.64

ROE (TTM)

DTIL-9160.0%

LYEL-9162.0%

ROA (TTM)

DTIL-4074.0%

LYEL-7050.0%

ROIC (TTM)

DTIL-6594.0%

LYEL-9162.0%

Cash

DTIL$86M

LYEL$73M

Debt

DTIL$22M

LYEL$0

Net Cash/Debt

DTIL$64M

LYEL$73M

Current Ratio (TTM)

DTIL12.82x

LYEL5.36x

Quick Ratio (TTM)

DTIL12.26x

LYEL5.12x

Debt/Equity (TTM)

DTIL0.50x

LYEL0.00x

Debt/Assets (TTM)

DTIL0.0%

LYEL0.0%

Interest Coverage (TTM)

DTILN/A

LYELN/A

Net Debt/EBITDA (TTM)

DTIL0.00x

LYEL0.00x

Beta

DTIL1.44

LYEL-0.04

52W Performance

DTIL17.9%

LYEL-52.3%

YTD Performance

DTIL63.9%

LYEL-69.9%

% from 52W High

DTIL-30.1%

LYEL-80.6%

% from 52W Low

DTIL90.4%

LYEL6.1%

Asset Turnover (TTM)

DTIL0.36x

LYEL0.00x

FCF Yield (TTM)

DTIL-30.2%

LYEL-86.2%

Earnings Yield (TTM)

DTIL-30.4%

LYEL-122.3%

Dividend Yield (TTM)

DTILN/A

LYELN/A

Rule of 40

DTIL3,356.7

LYEL-648,818.0

EV/GP/RG

DTILN/A

LYELN/A

Ticker research

View DTIL research View LYEL research

Metric	DTIL Precision BioSciences Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$173M	$203M
Enterprise Value	$110M	$130M
Price	$6.72	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	3.85x	7,526.09x
EV/Sales	2.44x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.85x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.09x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	80.94x	16,911.71x
Revenue & Growth
Revenue (TTM)	$45M	$27K
Revenue Growth (YoY)	3473.0%	-55.0%
Forward Rev Growth	-28.2%	7184.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-78.0%	-669059.3%
Net Margin (TTM)	-117.0%	-920285.2%
FCF Margin (TTM)	-116.3%	-648763.0%
Net Income (TTM)	$-53M	$-248M
FCF (TTM)	$-52M	$-175M
EPS (TTM)	-$2.04	-$10.64
ROE (TTM)	-9160.0%	-9162.0%
ROA (TTM)	-4074.0%	-7050.0%
ROIC (TTM)	-6594.0%	-9162.0%
Financial Health
Cash	$86M	$73M
Debt	$22M	$0
Net Cash/Debt	$64M	$73M
Current Ratio (TTM)	12.82x	5.36x
Quick Ratio (TTM)	12.26x	5.12x
Debt/Equity (TTM)	0.50x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.44	-0.04
52W Performance	17.9%	-52.3%
YTD Performance	63.9%	-69.9%
% from 52W High	-30.1%	-80.6%
% from 52W Low	90.4%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.00x
FCF Yield (TTM)	-30.2%	-86.2%
Earnings Yield (TTM)	-30.4%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,356.7	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View DTIL research	View LYEL research